3-D model for lung cancer mimics the real thing

October 11, 2012
3-D model for lung cancer mimics the real thing

(Medical Xpress)—A new technique that allows scientists to grow lung cancer cells in three dimensions could accelerate discoveries for a type of cancer that has benefited little from scientific research over the last several decades.

The , created by researchers at The Methodist Hospital and the University of Texas MD Anderson Cancer Center, uses biological matter to form miniature lungs that mimic the structure and function of real lung cancer, after which human are added. Findings from the model's first tests were recently published in the journal .

"We found that the 3-D model we devised worked in most respects much better than 2-D models currently being used in lung cancer research," said Min Kim, M.D., the study's principal investigator. "New models for lung cancer research are crucial because current models frequently do not correlate with the findings of human trials. The challenge is creating a model that we can study that can accurately predict what will happen in patients with lung cancer."

aiding the understanding and treatment of lung cancer have been limited and slow relative to breast and , among others. In 1975, the five-year survival rate for patients diagnosed with lung cancer was 13 percent. In 2005 (the most recent year for which reliable data are available), that survival rate had only increased to 16 percent.

"The lack of progress in finding effective treatments for lung cancer may be due, in part, to the lack of an that mimics the biological processes that occur in patients with lung cancer," said Dhruva Mishra, Ph.D. the paper's first author.

The Methodist-MD Anderson model uses a rat lung "matrix," a framework created after the rat have been chemically removed. This translucent matrix is then infused with human lung derived either from a patient or from a cell line. The cells that stick to the matrix are allowed to grow in nutrient rich, oxygenated broth that moves into and out of the lung space.

The model was first described by Mishra and many of his PLOS One co-authors in an Annals of Thoracic Surgery paper in April 2012. The present PLOS One paper reports the first tests of the model comparing its performance to other non-animal models.

The 2-D model Mishra and colleagues used for comparison is the conventional, flat surface flask, the most commonly used system for cell culture. Cells grow along one of the flattened sides below a shallow broth of nutrients. This model is commonly used in lung cancer research.

Mishra and his co-authors found that unlike the 2-D model, their 3-D model allowed the lung cancer to form "nodules," something the cancer does naturally in living tissue. The nodules are believed to play a crucial role in the cancer's growth and metastasis. The 2-D model produced an unnaturally high number of cells if left alone, whereas cell growth in the 3-D model provided more realistic cell growth and programmed cell death. The 3-D model also coaxed meaningful growth with preserved vasculature for inflow of nutrients and cells after four and six days showed signs of interacting with each other (also a natural phenomenon). in the 2-D model simply grew haphazardly to fill spaces.

The 3-D model also produced more matrix metalloproteinases, a family of enzymes that researchers believe are required for lung cancer cell growth. Other important gene products, caspase-3 and ki-67, were also measured at higher levels in the 3-D model.

"Our lab is exploring this novel 3-D model for to better understand the mechanism behind cancer metastasis," Kim said.

Explore further: Study identifies gene critical to development and spread of lung cancer

Related Stories

Study identifies gene critical to development and spread of lung cancer

April 24, 2012
A single gene that promotes initial development of the most common form of lung cancer and its lethal metastases has been identified by researchers at Mayo Clinic in Florida. Their study suggests other forms of cancer may ...

First and only therapeutic drug for ALK-positive lung cancer approved

August 31, 2011
In a major triumph for personalized medicine, the FDA approved the drug crizotinib for use with the lung cancer type known as ALK-positive.

Recommended for you

Outdoor light at night linked with increased breast cancer risk in women

August 17, 2017
Women who live in areas with higher levels of outdoor light at night may be at higher risk for breast cancer than those living in areas with lower levels, according to a large long-term study from Harvard T.H. Chan School ...

Scientists develop novel immunotherapy technology for prostate cancer

August 17, 2017
A study led by scientists at The Wistar Institute describes a novel immunotherapeutic strategy for the treatment of cancer based on the use of synthetic DNA to directly encode protective antibodies against a cancer specific ...

Toxic formaldehyde is produced inside our own cells, scientists discover

August 16, 2017
New research has revealed that some of the toxin formaldehyde in our bodies does not come from our environment - it is a by-product of an essential reaction inside our own cells. This could provide new targets for developing ...

Cell cycle-blocking drugs can shrink tumors by enlisting immune system in attack on cancer

August 16, 2017
In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs—designed to halt cancer ...

Researchers find 'switch' that turns on immune cells' tumor-killing ability

August 16, 2017
Molecular biologists led by Leonid Pobezinsky and his wife and research collaborator Elena Pobezinskaya at the University of Massachusetts Amherst have published results that for the first time show how a microRNA molecule ...

Popular immunotherapy target turns out to have a surprising buddy

August 16, 2017
The majority of current cancer immunotherapies focus on PD-L1. This well studied protein turns out to be controlled by a partner, CMTM6, a previously unexplored molecule that is now suddenly also a potential therapeutic target. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.